SelectQuote Q4 FY26 Shows Revenue Decline and Net Loss, Undermining Turnaround Narrative

What happened

SelectQuote reported fourth-quarter fiscal 2026 revenue of $321.7 million, down 6.8% from $345.1 million a year earlier, and swung to a consolidated net loss of $16.8 million compared to net income of $12.9 million in the prior-year quarter. The results fall short of the sequential trend from the third quarter, when revenue was $430.9 million and net income was $40.2 million, indicating a sharp deterioration in the fiscal fourth quarter. The decline is consistent with the risks highlighted in the DeepValue master report, which flagged softer Medicare Advantage submissions, lower carrier-sponsored incentives, and continued pressure on Healthcare Services profitability from medication costs. The master report had a WAIT rating predicated on clearing two near-term gates: NYSE continued listing compliance and confirmation of repeatable cash conversion, and this release does not provide positive evidence on either front. The absence of a reaffirmation of FY26 operating cash flow guidance (or its presence, if truncated) leaves the cash quality question unresolved, while the net loss may pressure the stock's ability to sustain the $1.00 bid required for NYSE compliance.

Implication

The fourth-quarter net loss breaks the pattern of recent profitability and suggests that the Senior segment's margin expansion may not be enough to offset revenue softness and cost pressures, directly challenging the base case that Senior profitability offsets weaker Medicare Advantage submissions and lower carrier incentives. If the full release shows that Healthcare Services Adjusted EBITDA remained depressed or worsened, it would indicate that the new PBM agreement has not yet translated into improved pharmacy economics, further weakening the bull case. The lack of operating cash flow information is critical because the master report's WAIT stance was contingent on confirming that FY26 operating cash flow lands within the guided $25–35 million range without relying on non-repeatable working capital timing benefits. Should the company fail to regain NYSE compliance by the September 2026 cure period deadline, the risk of suspension and forced corporate actions rises, which would likely cause further downside beyond the master report's bear case implied value of $0.55. Given these developments, investors should treat the thesis as under stress and require explicit confirmation of cash flow quality and listing compliance before considering positions; the probability of the bear scenario has likely increased.

Thesis delta

The Q4 FY26 net loss and revenue decline shift the thesis toward the bear scenario, as the expected offset from Senior profitability appears insufficient relative to the scale of deterioration. Previously, the base case assumed that Senior Adjusted EBITDA would offset softer Medicare Advantage submissions and lower carrier incentives, but a quarterly loss suggests those offsets may be weaker than modeled. While the WAIT rating remains appropriate until full financials and guidance are assessed, the probability of the bear case (implied value $0.55) has increased, and the bull case (implied value $1.20) now requires stronger evidence of PBM reimbursement improvement and cash conversion.